Table 1.
Recently available intravenous (IV) iron preparations.
| Name of the IV iron preparation | Status of registration | Indications | Test dose | Duration of infusion | Max dose in single infusion | Reference |
|---|---|---|---|---|---|---|
| ∗Ferumoxytol (Feraheme, AMAG Pharmaceuticals, Inc., USA) | FDA approved | Treatment of iron-deficiency anaemia in adult patients with CKD** | None | 1 minute | 510 mg | [46, 47] |
|
| ||||||
| ∗ Ferric carboxymaltose (Ferinject, Vifor Pharma, Glattbrugg, Switzerland) | Approved in Europe,FDA-approval is sought | Treatment of iron-deficiency anaemia in adult patients | None | 15 minutes | 20 mg/kg with max dose of 1000 mg | [48, 49] |
|
| ||||||
| ∗ Iron isomaltoside (MonoFer, Pharmacosmos A/S, Holbaek, Denmark) | Approved in Europe FDA-approval is sought | Treatment of iron-deficiency anaemia in adult patients with CKD** | None | 60 minutes | No max dose given at rate of 20 mg/kg | [50, 51] |
FDA, Food and Drug Administration; CKD, chronic kidney disease; Max, maximum. ∗No available data in pregnancy; however, if the benefit of treatment is judged to outweigh the potential risk to the fetus, the treatment should be confined to second and third trimester of pregnancy. ∗∗Extended approval is sought.